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Abstract
Background: The study investigated the pharmacokinetics of fosmidomycin when given alone and in
combination with clindamycin in patients with acute uncomplicated falciparum malaria.
Methods: A total of 15 and 18 patients with acute uncomplicated Plasmodium falciparum malaria who
fulfilled the enrollment criteria were recruited from out-patient department of Mae Sot Hospital, Tak
Province, Thailand. Patients were treated with monotherapy with fosmidomycin at the dose of 1,200 mg
every 8 hours for 7 days (n = 15) or combination therapy with fosmidomycin (900 mg every 12 hours for
7 days) and clindamycin (600 mg every 12 hours for 7 days) (n = 18). Blood samples were taken for
pharmacokinetic investigations of clindamycin and/or fosmidomycin and 24-hour urine samples were
collected during dosing period. Efficacy assessments included clinical and parasitological evaluation. Safety
and tolerability were assessed based on clinical and laboratory investigations.
Results: Both mono- and combination therapy regimens of fosmidomycin were well tolerated with no
serious adverse events. Combination therapy with fosmidomycin and clindamycin was proven highly
effective with 100% cure rate, whereas cure rate of monotherapy was 22% (28-day follow up).
Pharmacokientics of fosmidomycin following mono- and combination therapy were similar except Vz/F and
CL/F, which were significantly smaller in the combination regimen. Plasma concentration-time profiles of
both fosmidomycin and clindamycin were best fit with a one-compartment open model with first-order
absorption and elimination and with absorption lag time. Steady-state plasma concentrations of
fosmidomycin and clindamycin were attained at about the second or third dose. There was no evidence
of dose accumulation during multiple dosing. Urinary recovery of fosmidomycin was 18.7 and 20%
following mono- and combination therapy, respectively.
Conclusion: Pharmacokinetic dose optimization of fosmidomycin-clindamycin combination therapy with
the course of treatment of not longer than three days is required to obtain a regimen which is safe and
produced 100% cure for multidrug-resistant P. falciparum.
Published: 25 May 2007
Malaria Journal 2007, 6:70 doi:10.1186/1475-2875-6-70
Received: 4 December 2006
Accepted: 25 May 2007
This article is available from: http://www.malariajournal.com/content/6/1/70
© 2007 Na-Bangchang et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Malaria Journal 2007, 6:70 http://www.malariajournal.com/content/6/1/70
Page 2 of 10
(page number not for citation purposes)
Background
Malaria is one of the leading causes of morbidity and mor-
tality in the tropics with an annual estimate of 500 mil-
lion clinical cases and 2 million deaths [1]. The treatment
of malaria is becoming increasingly difficult due to Plas-
modium falciparum strains resistant to commonly used
antimalarials. In addition to the high-grade chloroquine-
resistant strains found in high frequencies in all endemic
areas of the world, resistance to sulphadoxine/pyrimeth-
amine is now common in large parts of Asia and South
America and is spreading to Africa as well. Development
of drug resistance and in some cases, concerns over safety,
highlight the urgent requirement for new antimalarial
drugs. Primarily directed towards the treatment of multi-
drug resistant P. falciparum, such drugs should possess
novel modes of action while being of proven efficacy and
safety.
Fosmidomycin is a phosphonic acid derivative previously
investigated as an antibacterial agent and later on has
been shown to be an effective malarial blood schizonti-
cide. It acts as a potent inhibitor of 1-deoxy-D-xylulose 5-
phosphate (DOXP) reductoisomerase, an essential
enzyme of the non-mevalonate pathway and therefore,
selectively blocks the biosynthesis of isopentenyl diphos-
phate and the subsequent development of isoprenoids in
P. falciparum [2-5]. The mevalonate independent biosyn-
thesis pathway for isoprenoides takes place in special
organelles of the parasites, the apicoplasts. These possess,
similarly to mitochondria or chloroplasts of green plants,
their own genome and can replicate independently of the
cell nucleus. Metabolic processes in the apicoplast are
similar to those found in bacteria and plants and differ
fundamentally from those of animal organisms. Fosmid-
omycin should, therefore, be very safe in humans in
whom isoprenoids are synthesized through a completely
different pathway. The drug has been shown in vitro and
in vivo in animal studies to be a potential antimalarial, but
the development of recrudescence found in early phase of
clinical trial precludes its use as monotherapy [6]. Drug
combinations are considered superior to monotherapy
with regards to pharmacodynamic synergistic effect and,
in addition, the delay of emergence of resistance to the
individual components. Clindamycin emerged as a
potential partner following the demonstration of in vitro
and in vivo synergistic activity [7]. A subsequent clinical
study in Gabon confirmed the effectiveness of this combi-
nation in children with asymptomatic malaria to be supe-
rior to fosmidomycin and clindamycin, when
administered as monotherapy, both in the initial clear-
ance of parasitaemia and in the prevention of recrudes-
cent infections [8,9]. It is not known, however, whether
concurrent administration of fosmidomycin and clin-
damycin would affect the pharmacokinetics of the indi-
vidual drugs.
The present pharmacokinetic study was part of two phase
II clinical trials for dose optimization of fosmidomycin
monotherapy (1,200 mg every 8 hours for 7 days) and
combination therapy with fosmidomycin (900 mg every
12 hours for 7 days) and clindamycin (600 mg every 12
hours for 7 days) [10]. The study was the first report that
characterize pharmacokinetic profiles of fosmidomycin
and clindamycin for dose optimization of fosmidomycin
mono- and combination therapy with clindamycin in
patients with multidrug-resistant falciparum malaria.
Patients and methods
Study design
This pharmacokinetic study was part of two open-label,
uncontrolled clinical trials to evaluate the clinical efficacy
and tolerability of two dosage regimens of fosmidomycin
mono- and combination therapy with clindamycin in
patients with acute uncomplicated falciparum malaria
conducted in Thailand during 2000–2002 [10]. Study
protocols were obtained from the Ethics Committees of
the Ministry of Public Health of Thailand and the Secretar-
iat Committee for Research Involving Human Subjects
(SCRIHS), the World Health Organization, Geneva, Swit-
zerland.
Patient
A total of 33 patients (15 Thais, 5 Karens, 13 Burmeses)
with acute uncomplicated P. falciparum malaria (mono-
infection) of either gender, who were admitted to Mae Sot
General Hospital, Tak Province, were included in the
pharmacokinetic study. Mae Sot is located on the western
border of Thailand-Myanmar and is well documented as a
multidrug resistance area. Patient inclusion criteria
included age between 18–50 years, each with a body
weight in excess of 40 kg, attending as outpatients with
signs/symptoms of acute uncomplicated malaria and par-
asitaemia levels between 1,000 and 50,000/µl. Subjects
were excluded if they were pregnant or breast-feeding, or
had a mixed infection, or significant concomitant disease,
or a haemoglobin of < 8.0 g/dl, or white cell count of >
12,000/µl (to exclude severe disease), or had received
antimalarial treatment within the previous 28 days.
Pre-treatment investigations consisted of clinical assess-
ments (general medical history, demographic data, drug
sensitivity and allergy, significant medical history, previ-
ous drug administration, physical examinations, monitor-
ing of vital signs and malaria signs and symptoms),
laboratory assessments (thick and thin blood smears for
parasite identification/quantification, urine test for chlo-
roquine [11] and sulphonamides [12], routine haematol-
ogy, serum biochemistry, urinalysis, and stool
examination for parasites and ova.Malaria Journal 2007, 6:70 http://www.malariajournal.com/content/6/1/70
Page 3 of 10
(page number not for citation purposes)
All patients were admitted to the hospitals for seven days
and were requested to complete follow-up visits on days
10, 14, 21 and 28 or until recrudescence occurred.
Drug administration
Fosmidomycin monotherapy
Patients were treated with oral doses of fosmidomycin
1,200 mg every 8 hours for 7 days. Fosmidomycin cap-
sules (batch no. 008003) were supplied by Alphamed
PHARBIL Arzneimittel GmbH (Germany); each capsule
containing 400 mg of fosmidomycin.
Fosmidomycin combination therapy
Patients were treated with oral fosmidomycin concur-
rently with clindamycin. Fosmidomycin was given at the
dose of 900 mg every 12 hours for 7 days. Fosmidomycin
capsules (batch no. FK 150–02007) were supplied by
Alphamed PHARBIL Arzneimittel GmbH; each capsule
containing 150 mg of fosmidomycin. Clindamycin was
given at the dose of 600 mg every 12 hours for 7 days.
Clindamycin film coated tablets (batch number 16843-
007) were supplied by Alphamed PHARBIL Arzneimittel
GmbH; each tablet containing 150 mg of clindamycin.
The patients fasted over night (8–10 hr) and emptied their
bladders immediately before drug administration. The
drugs were administered orally with 250 ml of water and
standard hospital meal (20–25% fat content) under
supervision of the assigned study staff. After ingestion of
drug tablets, patients were observed for 1 hr to ensure
retention of the drug. Patients who vomited any oral dose
of fosmidomycin or clindamycin were excluded from
pharmacokinetic data analysis. Meal was provided at 4 hr
post-dosing. Juices and water were freely available during
hospitalisation. Except for drugs described in the exclu-
sion criteria, all drugs necessary for the welfare of the
patients were allowed during the study period.
Blood and urine collection
A total of 15 blood samples (3 ml each) for pharmacoki-
netic investigations of fosmidomycin monotherapy were
collected from patients during days 0–7 of drug adminis-
tration as follows: at 0 (before first dose), 1, 2, 4, 8, 16, 24
(day 1), 48 (day 2), 72 (day 3), 96 (day 4), 120 (day 5),
144 (day 6), 168 (day 7), 192 and 216 h. For combination
therapy regimen, a total of 12 blood samples (5 ml each)
for pharmacokinetic investigations of fosmidomycin and
clindamycin were obtained from patients during days 0–
7 of dosing as follows: at 0 (before first dose), 24 (day 1),
48 (day 2), 156 (day 7), 157, 158, 160, 162, 164, 168, 174
and 180 hr from the commencement of dosing. Samples
collected at the time of drug administration were taken
prior to the dose. Blood samples were centrifuged (3,000
g, 15 min), and plasma samples were stored at -20°C until
analysis.
Twenty-four hours urine samples were collected from all
patients over 7–10 days from the commencement of dos-
ing. The volume of each urine collection was measured
and aliquots of 10 ml for the specified time periods were
collected into a 10 ml-polypropylene tube and stored at -
70°C until analysis.
Efficacy assessment
Efficacy assessments included clinical and parasitological
evaluation. Clinical signs/symptoms of malaria including
body temperature were monitored on days 0, 1, 2, 3, 4, 5,
6, 7, 10, 14, 21 and 28. Finger-prick blood smears were
examined at 6 hourly intervals until negative at 3 consec-
utive times, then daily during hospitalisation, on days 10,
14, 21 and 28. The films were stained with Giemsa stain
and parasite counts were determined by counting the
number of asexual parasites per 1,000 red blood cells on
a thin film or per 200 white blood cells on a thick film.
Analysis of the response to treatment was adapted from
the World Health Organization [13]. Efficacy was assessed
using the following parameters: (i) 28 day cure rate: the
proportion of patients with clearance of asexual parasites
within 7 days of treatment initiation without subsequent
recrudescence during 28 day follow-up); (ii) 7 day cure
rate: the proportion of patients with clearance of asexual
parasites within 7 days of treatment initiation; (iii) para-
site clearance time (PCT): defined as time from first dose
to continued clearance of asexual parasite forms which
remained for at least a further 48 h; and (iv) fever clear-
ance time (FCT): time from first dose until the first time
body temperature fell below 37.5°C and remained below
37.5°C for at least a further 48 hr.
Safety and tolerability assessment
Safety and tolerability of fosmidomycin monotherapy
and combination therapy with clindamycin were assessed
based on clinical findings or abnormal laboratory (hae-
matology and serum biochemistry) tests that first
occurred or increased in intensity within 7 days of treat-
ment initiation, and during follow up period on day 14,
21 and 28, in accord with the Common Toxicity Criteria
CTC grade [15].
Drug analysis
Determination of plasma and urine concentrations of fos-
midomycin and clindamycin were performed within six
months of sample collection. Stability of these two drugs
was found to be good under storage condition (-20°C) for
a minimum of twelve months [15,16]. Concentrations of
fosmidomycin in plasma and urine samples were deter-
mined by bioassay system based on agar disk diffusion
technique using Enterobacter cloacae ATCC 23355 as the
test organism [15]. The test medium was prepared from
Trypticase soy broth (BBL Microbiology Systems, MDs,
USA). The overnight culture in Trypticase soy broth wasMalaria Journal 2007, 6:70 http://www.malariajournal.com/content/6/1/70
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inoculated into the medium to give a final concentration
of 0.5% (v/v). Ten millilitres of the incubated agar
medium was poured into a 9-cm Petri dish and incubated
at 37°C for 18 to 20 hours. The zones of inhibition were
measured and concentrations were estimated from the
log-concentration-response curve. The precision of the
assay method based on within-day repeatability and
reproducibility (day-to-day variation) was below 5% (%
coefficient of variation: %C.V.). Good accuracy was also
observed for both the intra-day or inter-day assays. Limit
of quantification was 1 ng using 40 µl plasma or 7.5 µl
urine sample. The method was found to be comparable to
capillary electrophoresis method (HPCE).
Concentrations of clindamycin in plasma samples were
determined by high performance liquid chromatography
as described previously [16]. In brief, clindamycin was
separated from the internal standard (phenobarbital) on
a Luna C18 column (250 – 4.6 mm, 5 µm particle size:
Phenomenex™, USA), with retention times of 5.6 and 14.2
min, respectively. Ultraviolet detection was set at 210 nm.
The mobile phase consisted of a solution of 0.02 M diso-
diumhydrogenphosphate (pH 2.8) and acetonitrile
(76:24 v/v), running through the column at a flow rate of
1.0 ml/min. The chromatographic analysis was operated
at 25°C. Sample preparation (1 mL plasma) was done by
a single step liquid-liquid extraction with water saturated
ethylacetate. The precision of the method based on
within-day repeatability and reproducibility (day-to-day
variation) was below 15% (% coefficient of variations:
%C.V.) Good accuracy was observed for both the intra-
day or inter-day assays, as indicated by the minimal devi-
ation of mean values found with measured samples from
that of the theoretical values (below ± 15%). Limit of
quantification was accepted as 0.07 µg using 1 ml plasma
sample. The mean recoveries for clindamycin and the
internal standard were greater than 95%.
Pharmacokinetics
The non-compartmental pharmacokinetic analysis was
applied to determine the pharmacokinetic parameters of
fosmidomycin and clindamycin following a single initial
(fosmidomycin monotherapy) or last oral dose (fosmid-
omycin combination therapy) of fosmindiomycin and
clindamycin following oral administration. Cmax was the
maximum plasma concentrations and tmax was the time of
the maximum measured plasma concentrations following
a single initial or last dose. Cmin-obs was the observed
trough concentration. The area under the concentration-
time curve from time zero to the last sampling point that
yielded a quantifiable concentration (AUC0, t) was calcu-
lated with the log-linear trapezoidal method. At least the
last three sampling points were used to determine the
first-order constant associated with the terminal portion
of the curve (λz). Terminal phase elimination half-life (t1/
2z) was derived as t1/2z = ln(2)/λz. The AUC from time zero
to infinity (AUC0,  ∞) was calculated as AUC0-t + Ct/λz,
where Ct stands for the last measurable concentration.
Total clearance (CL/F) was calculated from Dose/AUC0,∞
and apparent volume of distribution (Vz/F) was calculated
as CL/F/λz, where F is bioavailability. Assuming bioavail-
ability (F) of 1 for both fosmidomycin and clindamycin,
maximum plasma concentration at steady-state (Cmax-ss),
minimum plasma concentration at steady-state (Cmin-ss)
and average plasma concentration at steady-state (Cave-ss)
following fast release oral formulation were estimated
from the relationships:
Cmin-ss = Cmax-ss.e-λ.τ
Where τ is dosing interval (hr).
Fluctuation between Cmax-ss  and Cmin-ss  was calculated
from the ratio between the two parameters.
In order to simulated plasma concentration-time profiles
of fosmidomycin and clindamycin when given as mono-
and combination therapy, one-compartment open model
with first-order absorption and elimination with absorp-
tion lag time were applied using ADAPT II, release 4.0
[17].
Statistical analysis
Descriptive statistics were calculated for pharmacokinetic
variables. Geometric means were determined for baseline
parasite counts. All pharmacokinetic parameters were pre-
sented as median (95% C.I.). Comparison of baseline
data (demographic, clinical, laboratory) with the data
obtained during follow up was performed using the Wil-
coxon-Signed Rank test. Comparison of the pharmacoki-
netic parameters between the two groups was performed
using the Mann-Whitney U test. The level of statistical sig-
nificance was set at α = 0.05 for all tests.
Results
Demographics, admission clinical and laboratory data of
the groups of patients are presented in Table 1. Most
patients had baseline laboratory parameters outside the
normal ranges; major parameters are presented in the
table. Most are common in patients with acute falciparum
malaria and all were mild or moderate in severity. A total
of 15 and 18 patients received treatment with fosmidomy-
cin monotherapy and combination therapy with clin-
damycin, respectively. Two patients (No 305, 314) who
C
Dose
VF e
ss
z
max
/( )
− − =
− 1 λ.τ
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received fosmidomycin monotherapy had successful
treatment, while the other nine cases developed recrudes-
cence and four lost to follow up during 28 day period.
Seven- and 28-day cure rate following monotherapy vs
combination therapy were 100 (10/10) and 22 (2/9)% vs
100 (12/12) and 100 (12/12)%, respectively. The corre-
sponding values [median (range) values] for FCTs and
PCTs for mono- vs combination therapy were 56 (24–
104) and 56 (8–80) hr vs 40 (24–72) and 40 (16–80) hr,
respectively. Concomitant medication included paraceta-
mol, dimenhydinate, diphenhydramine and chlorphe-
niramime.
Pharmacokinetics and urinary excretion
Observed and model-predicted (one-compartment model
with first-order absorption and elimination with absorp-
tion lag time) median plasma concentrations of fosmid-
omycin and clindamycin following monotherapy and
combination therapy are shown in Figures 1(a,b) and 2.
The pharmacokinetics of fosmidomycin given as mono-
therapy and combination therapy including pharmacoki-
netics of clindamycin given as combination therapy with
fosmidomycin in individual patients analysed by non-
compartmental pharmacokinetic analysis approach are
summarized in Table 2. Variability as expressed as % C.V.
for all parameters varied between 7.7 and 40.5%. Vz/F and
CL/F were significantly smaller following combination
therapy; other pharmacokinetic parameters were compa-
rable between the two treatment regimens.
Table 3 summarizes pharmacokinetics of fosmidomycin
and clindamycin analysed by one-compartment open
model with first order absorption and elimination with
absorption lag time. Steady-state plasma levels of fosmid-
omycin were reached at about 16–24 hr (third dose) fol-
lowing both regimens, while steady-state plasma levels of
clindamycin were reached at earlier time of 12–24 hr (sec-
ond dose).
Urinary concentrations of fosmidomycin were deter-
mined during the dosing period of 7–10 days and results
showed that percentage of total amount of fosmidomycin
excreted during 96–120 hr were markedly high following
both mono- and combination therapy of fosmidomycin.
There was no significant difference in urinary recoveries of
fosmidomycin (expressed as percent of dose adminis-
tered) following monotherapy and combination therapy
[median (95% C.I.): 18.7 (6.5–42.1) vs  20.0 (6.9–
43.3)%].
Relationship between plasma drug concentration and 
therapeutic outcome
Cmin-ss of fosmidomycin in two patients with successful
treatment on day 28 following fosmidomycin mono-
therapy were 2.16 and 1.24 µg/ml, while the levels in 9
patients who developed recrudescence were 1.19, 1.42,
2.79, 0.67, 0.27, 4.57, 1.95, 0.06 and 1.47 µg/ml. In the
group treated with fosmidomycin-clindamycin combina-
tion therapy, all were cured despite relatively low Cmin-ss of
0.20 µg/ml. The pharmacokinetics of fosmidomycin in
Table 1: Demographics, admission clinical and laboratory data of patients with acute uncomplicated falciparum malaria who were 
treated with fosmidomycin monotherapy and combination therapy with clindamycin. Data are presented as median (95% C.I.) or 
number of patients and percentage (n, %) values.
Characteristics Fosmidomycin monotherapy (N = 15) Fosmidomycin + Clindamycin (N = 18)
Age (yr) 36 (19–45) 29 (18–48)
Body weight (kg) 55 (42–67) 56 (40–75)
Male/Female 11/4 13/5
Ethnic:
Thai 5 10
Karen 2 3
Burmese 8 5
Body temperature (°C) 38.3 (36.0–40.0) 38.0 (37.3–39.9)
Baseline asexual form parasitaemia (/µl)a 11,747 (1,141–173,880) 30,600 (944–67,640)
Haemoglobin (mg/dl) 12.4 (8.0–15.5) 12.6 (8.1–15.0)
Haematocrit (%) 38.6 (26.5–44.8) 39.8 (25.5–45.7)
WBC (x109/l) 5.8 (3.5–8.7) 6.0 (3.0–8.9)
Platelet count (x109/l) 78 (22–230) 80 (21–225)
Total bilirubin (mg/dl) 1.5 (0.3–2.5) 1.3 (0.1–2.6)
ALT (IU/l) 25 (10–98) 24 (8–103)
Creatinine (mg/dl) 1.2 (0.9–1.8) 1.1 (0.7–1.9)
BUN (mg/dl) 13 (9–40) 14 (7–43)
Total protein (mg/dl) 6.2 (5.3–8.1) 6.0 (5.0–8.0)
Albumin (g/dl) 3.8 (3.0–4.6) 3.6 (2.9–4.5)
Glucose (mg/dl) 118 (80–198) 110 (79–205)
ageometric mean (range)Malaria Journal 2007, 6:70 http://www.malariajournal.com/content/6/1/70
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patients who had successful or treatment failure following
fosmidomycin monotherapy appeared to be similar.
Adverse effects
Fosmidomycin mono- and combination therapy with
clindamycin were well tolerated with no serious adverse
events, deaths or withdrawals due to adverse events. No
neutropaenia or drop in haemoglobin were observed as
previously reported in children [9]. Following fosmid-
omycin monotherapy, four (33.3%), three (25.0%), two
(12.5%) and three (25.0%) cases experienced headache,
epitaxis, vertigo and diarrhoea, respectively. Following
combination therapy with clindamycin, six (33.3%), one
(5.5%), one (5.5%), six (33.3%), three (16.7%) and one
(5.5%) cases experienced diarrhoea, dizziness, epitaxis,
headache, anorexiamacular rash, and myalgia respec-
tively. In addition, elevated ALT and hypokalaemia were
found in four (22.2%) and one (5.5%) cases, respectively.
All adverse events were categorized as mild or moderate in
severity. Significant within-subject differences over time
(days 0, 2, 4, 7, 28 or withdrawal) were found for all lab-
oratory parameters measured, which reflects changes nor-
mally encountered during a malarial infection.
Discussion
A bioassay based on disk diffusion technique was applied
for determination of fosmidomycin in plasma and urine
as the drug is the only bioactive compound. The analysis
of plasma concentrations of clindamycin was performed
by HPLC since bioassay lacks ability to discriminate
between clindamycin and its active metabolites (N-des-
methyl clindamycin and clindamycin sulphoxide) [18-
20]. Fosmidomycin and clindamycin were well absorbed
orally, but bioavailability of fosmidomycin may not be
complete which may be due to its high water solubility
property [21]. The bioavailability of fosmidomycin and
clindamycin have been reported to be 30 and 72%,
respectively [18,19,22]. Pharmacokinetics of fosmidomy-
cin and clindamycin following multiple oral dosing either
as mono- or combination therapy in patients with acute
uncomplicated falciparum malaria observed in this study
are comparable with those reported in healthy subjects
following a single dose of 500 mg or multiple doses of
250 or 500 mg given every 6 hours [21,23,24]. In single
dose studies, mean peak plasma concentrations of 2.45
µg/ml were attained following doses of 500 mg. In
repeated dose studies in which fosmidomycin was admin-
istered every 6 hours for periods of 5 to 7 days in doses of
250, 500 mg and 1 g, steady-state concentrations of 2.45,
4.01 and 5.0 µg/ml, respectively were achieved after 24 hr.
Plasma concentration-time profiles of both drugs were
best fitted with a one-compartment open model with first-
order absorption and elimination with absorption lag
time. It is noted for a marked variability in fluctuation of
Cmax-ss and Cmin-ss of fosmidomycin and clindamycin fol-
lowing multiple dosing regimens. The trough/peak
plasma concentrations after both dosage regimens
increased up to the second or third dose and remained at
Observed and predicted median plasma concentrations of  fosmidomycin (by one-compartment open model with first- order absorption and elimination with absorption lag time)  given as (a) monotherapy (1,200 mg every 8 hours for 7  days), and (b) combination therapy with clindamycin (900 mg  every 12 hours for 7 days) Figure 1
Observed and predicted median plasma concentrations of 
fosmidomycin (by one-compartment open model with first-
order absorption and elimination with absorption lag time) 
given as (a) monotherapy (1,200 mg every 8 hours for 7 
days), and (b) combination therapy with clindamycin (900 mg 
every 12 hours for 7 days).
(a)
(b)
Observed and predicted median plasma concentration of  clindamycin (by one compartment open model with first- order absorption and elimination with absorption lag time)  given as combination therapy with fosmidomycin (600 mg  every 12 hours for 7 days) Figure 2
Observed and predicted median plasma concentration of 
clindamycin (by one compartment open model with first-
order absorption and elimination with absorption lag time) 
given as combination therapy with fosmidomycin (600 mg 
every 12 hours for 7 days).Malaria Journal 2007, 6:70 http://www.malariajournal.com/content/6/1/70
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steady-state thereafter. Fosmidomycin was not metabo-
lised and excreted unchanged in urine as a bioactive sub-
stance. The urinary recovery expressed as percent of the
administered doses were relatively low (18 and 20% fol-
lowing mono- and combination therapy) comparing to
those reported in healthy subjects (26%) [24,25]. This
extent of urinary excretion supports the low bioavailabil-
ity of the drug after oral dose administration. Elimination
of both fosmidomycin and clindamycin were not affected
by dosing, which suggests no accumulation and dose lin-
earity. This was supported by the consistency of Cmax-ss
and Cav-ss values, the unchanged elimination half-lives
after the first and last dose, and the constant urinary recov-
ery during 0–7 days of dosing. In a previous study, satu-
rated absorption of fosmidomycin after multiple dosing
was suggested as there were a progressive decline in total
urinary recovery from 35.9 to 22.4% during multiple dos-
ing [21].
The non-compartment pharmacokinetic analysis of fos-
midomycin monotherapy was investigated during the
acute phase of malaria infection on the first day whereas
its kinetics following combination therapy with clin-
damycin was investigated following the last dose on day
7. Data suggest that malaria infection may not have signif-
icant influence on the pharmacokinetics of both fosmid-
omycin and clindamycin. Although amount of
fosmidomycin excreted in urine appears to be relatively
low in patients with malaria compared with healthy sub-
jects, overall pharmacokinetic profiles were similar. The
Table 3: Pharmacokinetics of fosmidomycin and clindamycin analysed by one-compartment model with first order absorption and 
elimination with absorption lag-time. Data are presented as median (%C.V) values.
Pharmacokinetic parameters Fosmidomycin monotherapy 
(N = 15)
Fosmidomycin + Clindamycin (N = 18)
Fosmidomycin Clindamycin
Cmax (µg/ml) 3.95 (12.8) 4.06 (6.8) 5.98 (5.1)
tmax (hr) 2.24 (28.1) 2.46 (11.6) 1.14 (2.4)
K01 (/hr) 1.27 (104.3) 1.17 (2.5) 3.99 (111.3)
K10 (/hr) 0.20 (24.7) 0.18 (12.5) 0.22(0.1)
tlag (hr) 0.5 (83.3) 0.6 (15.4) 0.38(17.6)
AUC0, (µg.hr/ml) 27.67 (7.6) 35.59 (4.1) 31.9(75.9)
t1/2a (hr) 0.5 (104.0) 0.6 (39.9) 0.17(4.8)
t1/2e (hr) 3.4 (24.7) 3.8 (13.0) 3.11(0.7)
Vz/F (l) 214.00 (27.4) 138.00 (14.9) 84 (21.0)
CL/F (l/hr) 433.66 (7.7) 252.85(4.1) 18.79(44.0)
k01 = absorption rate constant; k10 = elimination rate constant; tlag= absorption lag time; t1/2a = absorption half-life; t1/2e= elimination half-life
Table 2: Pharmacokinetics of fosmidomycin and clindamycin analysed by non-compartmental model in patients with acute 
uncomplicated falciparum malaria. Data are presented as median (95% C.I.) values.
Pharmacokinetic parameters Fosmidomycin monotherapy (N = 15) Fosmidomycin + Clindamycin (N = 18)
Fosmidomycin Clindamycin
Cmax (µg/ml) 4.58 (2.32–6.77) 5.86 (2.79–12.52) 7.34 (4.88–12.73)
tmax (hr) 2 (1–4) 2 (1–4) 1 (1–2)
Ctrough-obs (µg/ml) 1.90 (0.92–2.99) 0.40 (0.0–2.01) 1.32 (0.39–3.42)
Cmin-ave (µg/ml) 1.47 (0.06–9.96) 1.06 (0.20–2.98) 0.17 (0.01–0.78)
Cmax-ave (µg/ml) 7.22 (1.52–15.84) 8.67 (4.21–14.23) 6.63 (3.96–9.52)
Css-ave (µg/ml) 3.74 (3.18–12.52) 2.93 (1.97–6.98) 1.91 (1.20–3.06)
Fluctuation 5.1 (1.6–47.6) 10.5 (3.6–40.3) 1.1 (0.7–1.6)
AUC0, t (µg.hr/ml) 22.91 (12.65–33.32) 35.00 (20.41–78.90) 31.80 (15.84–370.67)
AUC0,((µg.hr/ml) 29.7 (25.06–100.16) 39.13 (24.29–85.55) 31.91 (19.28–50.49)
λ Z (/hr 0.201 (0.06–0.48) 0.196 (0.107–0.308) 0.272 (0.156–0.464)
T1/2z (/hr) 3.4 (1.4–11.8) 3.5 (2.2–6.5) 2.6 (1.5–4.4)
VZ/F (l) 211.40 (96.84–823.04) 116.21 (69.94–267.45)a 67.50 (46.56–135-87)
CL/F (l/hr) 40.08 (11.97–47.18) 25.94 (10.74–38.13)b 18.77 (11.77–30.12)
a = Statistically significant difference with monotherapy with p-value = 0.004
b = Statistically significant difference with monotherapy with p-value < 0.0001Malaria Journal 2007, 6:70 http://www.malariajournal.com/content/6/1/70
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pharmacokinetics of fosmidomycin when given alone or
with clindamycin were generally comparable except for
the significant paralleled reduction of Vz/F and CL/F when
clindamycin doses were added, while t1/2z  remained
unchanged. It is not clear whether these changes are con-
tributed mainly by malaria infection or pharmacokinetic
interaction with clindamycin or both. Reduction of renal
clearance of fosmidomycin when clindamycin was given
concurrently may account partly for this pharmacokinetic
difference. Fosmidomycin is only eliminated by renal
clearance while clindamycin is metabolised by CYP3A in
liver to clindamycin sulphoxide and N-desmethyl clin-
damycin [25]. Plasma protein binding of fosmidomycin
in human is about 1% but clindamycin binds extensively
about 90% to plasma protein, mainly to α1-acid glycopro-
tein [19-23]. Therefore, the interaction if actually
occurred, cannot be explained at the level of hepatic
metabolism or plasma protein binding displacement.
Fosmidomycin monotherapy was shown safe and effec-
tive blood schizonticide in the initial clearance of asexual
parasitaemia. However, the high rate of recrudescence pre-
cludes its use in monotherapy [6,10] Monotherapy with
fosmidomycin was investigated in a pilot study for 1,200
mg every eight hours for seven days with cure rate of 100%
(10/10). When the duration was reduced to five, four and
three days, cure rates decreased to 89, 88 and 60%, respec-
tively. These observations signify the importance of opti-
mal fosmidomycin dose regimens in the treatment of
malaria. In the present study, the cure rate of 22% was
observed with monotherapy with fosmidomycin at a dose
of 1,200 mg administered orally every eight hours for
seven days in a total of 15 Thai patients [10]. The cure rate
with the same dose regimen was, however, 100% in Gam-
bian patients [10]. MIC (minimum inhibitory concentra-
tion) of fosmidomycin for the treatment of multidrug
resistant falciparum malaria remains to be determined but
is expected to be higher than that in Gambian isolates.
The IC50 value for recombinant P. falciparum DOXP reduc-
toisomerase is approximately 40 nM and varied from 300
to 1,200 nM in P. falciparum in vitro without obvious
cross-resistance with other antimalarials [7,26]. Plasma
concentrations in two patients with successful treatment
following monotherapy were as high as 1.24 and 2.1 µg/
ml, which are considered adequate for radical cure. It was
noted that some patients among the 10 cases had recru-
descence despite plasma concentrations markedly greater
than these levels (4.52 µg/ml). This suggests intrinsically
low sensitivity of some parasite strains in Thailand to fos-
midomycin and that monotherapy of the drug may not be
effective for treatment of multidrug resistant falciparum
malaria. When fosmidomycin was given with clindamy-
cin (900 mg fosmidomycin in combination with clin-
damycin at 600 mg administered orally every 12 hours for
7 days) on the other hand, radical cure was achieved in all
patients even with the trough concentrations of as low as
0.2 µg/ml. This could be explained by pharmacodynamic
synergistic interaction between fosmidomycin and clin-
damycin on parasite enzyme DOXP reductoisomerase.
Clindamycin targets the prokaryote-like ribosomes of the
apicoplast and by this means inhibits self-replication of
the organelle [27,28]. As a consequence of this mecha-
nism, the drug displays a typical delayed kill kinetic effect,
the growth of parasites being unaffected until the second
replication after drug exposure. Under such conditions,
the in vitro growth of P. falciparum is inhibited with an
IC50 and IC90 of approximately 25 and 50 nM, respec-
tively. As a consequence of its high activity but slow onset
of activity, clindamycin is recommended for the treatment
of asymptomatic malaria or in combination with other
antimalarials. It has been suggested that time-dependent
antimicrobial agents should remain above the MIC of
pathogens for at least three malaria cycle of seven days.
Unlike fosmidomycin, recent studies have suggested that
clindamycin displays concentration-dependent bacterio-
cidal activity [17,29] while exhibiting an in vitro post anti-
biotic effect (PAE) for certain period. In vivo, the PAE is
generally longer and due to effects such as post antibiotic
leukocyte enhancement and post-antibiotic sub-MIC
effect. Frequent dosing interval of clindamycin regimen is
therefore not necessary. The recommended oral dosing of
clindamycin for bacterial infection was 600 mg every 6 hr
or 900 mg every 8 hr. However, it was later shown that the
pharmacokinetics and concentration-time profiles were
comparable with the dosing regimen 1,200 mg every 12
hr which is more practical for clinical application. This
may explain the sustained antimalarial efficacy when clin-
damycin was used with fosmidomycin despite low mini-
mum plasma concentrations of fosmidomycin at steady-
state. Whether the antimalarial activity of clindamycin
bioactive metabolites should also be considered when
performing a pharmacokinetic/pharmacodynamic evalu-
ation has not yet been elucidated. In human, the forma-
tion of N-desmethyl clindamycin and its excretion in
urine and faece have been confirmed [25] but the metab-
olite could not be detected in the plasma of patients [30].
The currently suggested dose regimens are based on par-
ent compound concentrations only and the presence of
metabolite activity (if any) would only amplify the posi-
tive therapeutic outcome. Further study is required for
dose optimization of the appropriate ratio of fosmidomy-
cin and clindamycin combination including dosing inter-
val with shorter course of at least 3 days that is safe and
effective (produces 100% cure) for treatment of multidrug
resistant falciparum.
Abbreviations
AUC Area under the plasma concentration-time curve
Cmin-obs Observed trough concentrationMalaria Journal 2007, 6:70 http://www.malariajournal.com/content/6/1/70
Page 9 of 10
(page number not for citation purposes)
Cmax Maximum plasma concentration
Cmax-ss Maximum plasma concentration at steady-state
Cave-ss Average plasma concentration at steady-state
CI Confidence interval
CL Total clearance
CV Coefficient of variation
F Bioavailability
FCT Fever clearance time
HPCE High performance capillary electrophoresis
HPLC High performance liquid chromatography
IC50 Fifty percent inhibitory concentration
MIC Minimum inhibitory concentration
PAE Post antibiotic effect
PCT Parasite clearance time
tmax Time to maximum plasma concentration
Vz Apparent volume of distribution
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